Understanding how a protein regulates harmful tau in Alzheimer's disease
Official title: Investigating how SUT-6/NIPP1 regulates pathological tau
Funded at Seattle Inst for Biomedical/clinical Res · NIH-11145281 · Data updated 2026-11-12
This study is looking at how a specific protein called SUT-6/NIPP1 can help reduce the harmful effects of a protein that builds up in the brains of people with Alzheimer's and similar diseases, with the hope of finding new ways to treat these conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Seattle Inst for Biomedical/clinical Res NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | August 1, 2024 |
| Project end | April 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $503,306 |
| NIH project number | 5R01AG084552-02 |
| Project ID | NIH-11145281 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or related dementias, particularly those experiencing symptoms related to tau protein accumulation.
✕Less likely to help
Patients with tauopathies not related to Alzheimer's disease or those with other neurodegenerative conditions may not benefit from this research.
What this research studies
This research investigates the role of the SUT-6/NIPP1 protein in regulating the toxicity caused by abnormal tau protein accumulation, which is a key feature of Alzheimer's disease and related dementias. Using a model organism, researchers will perform genetic screenings to identify how changes in SUT-6/NIPP1 can suppress tau-induced toxicity. The study aims to uncover the molecular mechanisms behind tauopathies, potentially leading to new therapeutic targets for treating these conditions.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow down or reverse the effects of Alzheimer's disease and related dementias.
How similar studies have gone: Previous research has shown promise in targeting tau protein mechanisms, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
-
Seattle Inst for Biomedical/clinical Res
Seattle, United States Active
Researchers
- Principal investigator: Kow, Rebecca Liang — Seattle Inst for Biomedical/clinical Res
- Study coordinator: Kow, Rebecca Liang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.